What is HC Wainwright's Forecast for MIRM FY2026 Earnings?

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Mirum Pharmaceuticals to a loss of $0.37 per share from a prior estimate of $3.78, while maintaining a Buy rating and $140 price target.
• Mirum reported a quarterly loss of $1.06 per share, missing the $0.74 consensus estimate, but revenue of $176.24 million exceeded expectations and increased 37.9% year over year.
• Analyst sentiment remains favorable, with an average “Moderate Buy” rating and consensus price target of $137.33, despite recent insider selling and Mirum’s continued negative profitability metrics.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Equities research analysts at HC Wainwright upped their FY2026 earnings per share estimates for Mirum Pharmaceuticals in a research report issued to clients and investors on Thursday, August 6th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.37) per share for the year, up from their prior estimate of ($3.78). HC Wainwright currently has a "Buy" rating and a $140.00 price target on the stock. The consensus estimate for Mirum Pharmaceuticals' current full-year earnings is ($4.42) per share.

Several other research firms also recently commented on MIRM. Morgan Stanley set a $137.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday. Weiss Ratings raised Mirum Pharmaceuticals from a "sell (d-)" rating to a "sell (d)" rating in a report on Thursday. Raymond James Financial reiterated a "strong-buy" rating and issued a $165.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Citigroup reaffirmed an "outperform" rating on shares of Mirum Pharmaceuticals in a report on Thursday. Finally, Robert W. Baird set a $123.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $137.33.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ MIRM opened at $98.70 on Tuesday. The company has a market cap of $6.41 billion, a PE ratio of -6.78 and a beta of 0.52. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.86. The business has a 50-day simple moving average of $110.38 and a two-hundred day simple moving average of $101.91. Mirum Pharmaceuticals has a fifty-two week low of $58.48 and a fifty-two week high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.32). The company had revenue of $176.24 million for the quarter, compared to analysts' expectations of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The firm's quarterly revenue was up 37.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.12) EPS.

Institutional Trading of Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Cullen Frost Bankers Inc. purchased a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at about $30,000. Eurizon Capital SGR S.p.A. purchased a new stake in Mirum Pharmaceuticals in the fourth quarter valued at approximately $32,000. CIBC Private Wealth Group LLC purchased a new stake in Mirum Pharmaceuticals in the fourth quarter valued at approximately $32,000. Quantbot Technologies LP acquired a new stake in shares of Mirum Pharmaceuticals in the third quarter valued at approximately $33,000. Finally, Comerica Bank boosted its holdings in shares of Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company's stock valued at $40,000 after acquiring an additional 278 shares during the period.

Insider Activity at Mirum Pharmaceuticals

In other news, CEO Christopher Peetz sold 30,000 shares of the company's stock in a transaction on Monday, June 1st. The shares were sold at an average price of $95.84, for a total value of $2,875,200.00. Following the completion of the transaction, the chief executive officer owned 194,309 shares in the company, valued at approximately $18,622,574.56. This represents a 13.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 2,721 shares of the business's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $120.00, for a total transaction of $326,520.00. Following the completion of the sale, the senior vice president directly owned 3,114 shares of the company's stock, valued at approximately $373,680. This trade represents a 46.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 67,155 shares of company stock worth $7,185,662 in the last three months. 8.32% of the stock is owned by company insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source